Characterization of pediatric patients with medulloblastoma in a referral center in Bogotá from 2011 to 2018

Caracterización de pacientes pediátricos con meduloblastoma tratados en un centro de referencia en Bogotá en el periodo 2011 a 2018

Published 2022-11-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 9 No. 1 (2022): Enero-junio
Section
Original articles
How to Cite
Characterization of pediatric patients with medulloblastoma in a referral center in Bogotá from 2011 to 2018.
Rev. colomb. hematol. oncol. [Internet]. 2022 Nov. 1 [cited 2025 Jan. 10];9(1):10-8. Disponible en: https://doi.org/10.51643/22562915.392
DOI

https://doi.org/10.51643/22562915.392
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Edgar Cabrera
HOMI Fundación Hospital Pediátrico La Misericordia
    https://orcid.org/0000-0001-9494-1263
    Cindy Martinez
    Universidad Nacional de Colombia.
      https://orcid.org/0000-0003-1756-6812
      Nelson Aponte
      HOMI Fundación Hospital Pediátrico La Misericordia
        https://orcid.org/0000-0001-6238-9750
        Johnny García
        HOMI Fundación Hospital Pediátrico La Misericordia
          https://orcid.org/0000-0001-5243-2209
          Show authors biography

          Central nervous system (CNS) tumors are the most prevalent solid neoplasms in pediatrics. Medullo- blastoma is the most frequent embryonal tumor of the CNS and corresponds to approximately 20% of cases. Objective: to describe the experience in the diagnosis, treatment, and results of patients with medulloblastoma in a reference center in Colombia. Methods: 38 patients were included from January 2011 to December 2018. Results: those under 3 years of age received treatment based on the CCG9921 protocol and those over 3 years of age treatment based on the ACNS0332 protocol. Overall survival at 5 years was 50.6%. The overall survival of the entire group is low compared to countries with higher incomes due to multiple factors such as access barriers. Conclusion: It is im- portant to establish national guidelines that allow earlier diagnosis and risk-adjusted treatment. Also, it is important to collect information from multiple centers in order to evaluate the results and propose improvements in health policies.

          Article visits 527 | PDF visits 570

          1. Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. [Internet] 2012;19(11):1541-1544. Disponible en: https://doi.org/10.1016/j.jocn.2012.04.009
          2. Dhall G. Medulloblastoma. J Child Neurol. [Internet] 2009;24(11):1418-1430. Disponible en: https://doi.org/10.1177/0883073809341668
          3. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol. [Internet] 2018;20:iv1-iv86. Disponible en: https://doi.org/10.1093/neuonc/noy131
          4. Blaney S, Adamson P, Helman L. Pizzo and Poplack´s Pediatric Oncology. 8th edition. Wolters Kluver; 2021.
          5. Khanna V, Achey RL, Ostrom QT, Block- Beach H, Kruchcko C, et al. Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. J Neurooncol. [Internet] 2017;135(3):433-441. Disponible en: https://doi.org/10.1007/s11060-017-2594-6
          6. Johnston D, Keene D, Kostova M, Strother D, Lafay -Cousin L, et al. Incidence of medulloblastoma in canadian children. J Neurooncol. [Internet] 2014;120:575-579. Disponible en: https://doi.org/10.1007/s11060-014-1588-x
          7. Ezzat S, Kamal M, El-Khateeb N, El- Beltagy M, Taha H, et al. Pediatric brain tumors in a low/middle income country: Does it differ from that in developed world? J Neurooncol. [Internet] 2016;126(2):371-376. Disponible en: https://doi.org/10.1007/s11060-015-1979-7
          8. Makino K, Nakamura H, Yano S, Kuratsu JI, Kunamoto Brain Tumor Group. Population-based epidemiological study of primary intracranial tumors in childhood. Child’s Nerv Syst. [Internet] 2010;26(8):1029-1034. Disponible en: https://doi.org/10.1007/s00381-010-1126-x
          9. Waszak SM, Northcott P, Buchhalter I, Robinson G, Sutter C, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. [Internet] 2018;19:785-798. Disponible en: https://doi.org/10.1016/S1470-2045(18)30242-0
          10. Northcott PA, Robinson GW, Kratz CP, Mabott DJ, Pomeroy SL, et al. Medulloblastoma. Nat Rev Dis Prim. [Internet] 2019;5(1). Disponible en: https://doi.org/10.1038/s41572-019-0063-6
          11. Millard NE, De Braganca KC. Medulloblastoma. J Child Neurol. [Internet] 2016;31(12):1341-1353. Disponible en: https://doi.org/10.1177/0883073815600866
          12. Wilne S, Collier J, Kennedy C, Koller K, Grundy R, Walker D. Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol. [Internet] 2007;8(8):685-695. Disponible en: https://doi.org/10.1016/S1470-2045(07)70207-3
          13. Rochkind S, Blatt I, Sadeh M, Goldhammer Y. Extracranial metastases of medulloblastoma in adults: Literature review. J Neurol Neurosurg Psychiatry. [Internet] 1991;54(1):80-86. Disponible en: https://doi.org/10.1136/jnnp.54.1.80
          14. Ellison DW. Childhood medulloblastoma- novel approachesto the classification of a heterogeneous disease.pdf. Acta Neuropathol. [Internet] 2010;120(305-316). Disponible en: https://doi.org/10.1007/s00401-010-0726-6
          15. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. [Internet] 2021;23(8):1231-1251. Disponible en: https://doi.org/10.1093/neuonc/noab106
          16. Pizer BL, Clifford SC. The potential impact of tumour biology on improved clinical practice for medulloblastoma: Progress towards biologically driven clinical trials. Br J Neurosurg. [Internet] 2009;23(4):364-375. Disponible en: https://doi.org/10.1080/02688690903121807
          17. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho Y, et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol. [Internet] 2012;123(4):465-472. Disponible en: https://doi.org/10.1007/s00401-011-0922-z
          18. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun L, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. [Internet] 2006;7(10):813-820. Disponible en: https://doi.org/10.1016/S1470-2045(06)70867-1
          19. Packer RJ, Gajjar A, Vezina G, Rorke- Adams L, Burguer P, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. [Internet] 2006;24(25):4202-4208. Disponible en: https://doi.org/10.1200/JCO.2006.06.4980
          20. Von Bueren AO, Kortmann RD, Von Hoff K, Friedrich C, Mynarek M, et al. Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol. [Internet] 2016;34(34):4151-4160. Disponible en: https://doi.org/10.1200/JCO.2016.67.2428
          21. Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: Results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol. [Internet] 2012;30(26):3187-3193. Disponible en: https://doi.org/10.1200/JCO.2011.39.8719
          22. Geyer JR, Sposto R, Jennings M, Boyett J, Axtell R, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A Report from the Children’s Cancer Group. J Clin Oncol. [Internet] 2005;23(30):7621-7631. Disponible en: https://doi.org/10.1200/JCO.2005.09.095
          23. Leary S, Packer R, Li Y, Bilups C, Smith K, et al. Efficacy of Carboplatin and Isotretinoin in children with High-risk Medulloblastoma: A randomized clinical trial from the Children´s Oncology Group. JAMA Oncol. [Internet] 2021; 7(9), 1313-1321 Disponible en: https://doi.org/10.1001/jamaoncol.2021.2224
          24. Hwang EI, Kool M, Burger PC, Capper D, Chevez L, et al. Extensive molecular and clinical heterogeneity in patients with histologically diagnosed CNS-PNET treated as a single entity: A report from the children’s oncology group randomized ACNS0332 trial. J Clin Oncol. [Internet] 2018;36(34):3388-3395. Disponible en: https://doi.org/10.1200/JCO.2017.76.4720
          25. Hoff K von, Hinkes B, Gerber NU, Deinlein F, Mittler U, et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT’91. Eur J Cancer. [Internet] 2009;45(7):1209-1217. Disponible en: https://doi.org/10.1016/j.ejca.2009.01.015
          26. Taylor RE, Bailey CC, Robinson KJ, Weston CL, Ellison D, et al. Impact of radiotherapy parameters on outcome in the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma. Int J Radiat Oncol Biol Phys. [Internet] 2004;58(4):1184–1193. Disponible en: https://doi.org/10.1016/j.ijrobp.2003.08.010

          Information

          Directories and indexers
          Google Scholar profile

          QR code

          Keywords

          Most read in the last 30 days

          Current Issue

          Sistema OJS 3.4.0.7 - Metabiblioteca |